LENZ: LENZ Therapeutics, Inc. - Summary | Jitta

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Price
$7.01
Loss Chance
58.9%
n/aJITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Sorry, the data is not yet available for this stock.
Jitta Factors
Growth Opportunity (11)
Recent Business Performance (39)
Financial Strength (38)
Return to Shareholders (0)
Competitive Advantage (18)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 170.57% in the last quarter (yoy)
CapExVery High
Key Stats
Jitta Score
Jitta Line
n/a
100.00%
3.05
191.75%
3.06
159.05%
Pharmaceuticals
4.95
55.20%
5.05
80.43%
5.69
90.37%
COMPANY DESCRIPTION
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.